BioNTech acquires Neon at cheapest for $67...mRNA cancer neoantigen specialist BioNTech AG is set to buy all shares of Neon Therapeutics, Inc. expanding its pipeline of neoantigen-targeting therapies and getting foothold in the US. more ➔
New stromal target overcomes cancer resist...British researchers have identified several small molecule drugs that sensitized B cell cancers to chemotherapy and extended survival in mouse models. more ➔
Astellas and Adaptimmune team up in CAR-T...Adaptimmune Therapeutics plc and Japanese Astellas Pharma, Inc. have signed a discovery partnership to develop off-the-shelf allogeneic T cell-based cancer therapies from stem cells. more ➔
Illumina embraces RocheTwelve years after Roches $6.8bn hostile takeover bid for Illumina, the companies have entered into a 15-year partnership to boost personalised NGS-based cancer testing. more ➔
Incyte licenses Morphosys tafasitamab in...Incyte Corp. has signed a global license agreement for commercialisation of Morphosys AGs anti-CD-19 programme tafasitamab. more ➔
Novadiscovery takes off with €5 Series A...In silico clinical trials pioneer Novadiscovery SA has raised €5m in a series A financing led by Swiss Debiopharm Innovation Fund. more ➔
Alderaan Biotechnology raise €18.5m in S... Following a €1.5m seed financing in 2017, cancer specialist Alderaan Biotechnology SAS has raised €18.5m in a Series A round led by Advent France Biotechnology and Medicxi. more ➔
North Sea Therapeutics raises US$40m in Se...NorthSea Therapeutics BV has raised US$40m to provide proof-of-concept of its NASH drug icosabutate. more ➔
Merck and 4SC collaborate in immunooncolog...4SC AG and Merck KgaA have signed a supply agreement to start clinical tests of Mercks checkpoint blocker avelumab plus 4SCs HDAC I blocker domatinostat. more ➔
Novo Holdings invest US$12m in AMR compani...Mutabilis and IBT Vaccines have successfully bagged US$12m from the Novo Holdings REPAIR Impact Fund. more ➔